These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 34147295)

  • 1. CCL3, CCL5, IL-15, IL-1Ra and VEGF compose a reliable algorithm to discriminate classes of adverse events following 17DD-YF primary vaccination according to cause-specific definitions.
    Fradico JRB; Campi-Azevedo AC; Peruhype-Magalhães V; Coelho-Dos-Reis JGA; Faria ES; Drumond BP; de Rezende IM; Almeida JF; da Silva RB; Gusmão JD; Arcoverde Medeiros EL; Rodrigues RCM; Ribeiro JGL; Pereira MA; Silva MVF; Rocha MLC; Adelino TER; de Melo Iani FC; Pereira GC; Fernandes EG; Auxiliadora-Martins M; Valim V; de Souza Gomes M; Amaral LR; Romano APM; Ramos DG; Carvalho SMD; Fantinato FFST; do Carmo Said RF; Teixeira-Carvalho A; Martins-Filho OA
    Vaccine; 2021 Jul; 39(31):4359-4372. PubMed ID: 34147295
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adverse events following yellow fever preventive vaccination campaigns in eight African countries from 2007 to 2010.
    Breugelmans JG; Lewis RF; Agbenu E; Veit O; Jackson D; Domingo C; Böthe M; Perea W; Niedrig M; Gessner BD; Yactayo S;
    Vaccine; 2013 Apr; 31(14):1819-29. PubMed ID: 23395587
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Multi-parameter approach to evaluate the timing of memory status after 17DD-YF primary vaccination.
    Costa-Pereira C; Campi-Azevedo AC; Coelho-Dos-Reis JG; Peruhype-Magalhães V; Araújo MSS; do Vale Antonelli LR; Fonseca CT; Lemos JA; Malaquias LCC; de Souza Gomes M; Rodrigues Amaral L; Rios M; Chancey C; Persi HR; Pereira JM; de Sousa Maia ML; Freire MDS; Martins RM; Homma A; Simões M; Yamamura AY; Farias RHG; Romano APM; Domingues CM; Tauil PL; Vasconcelos PFC; Caldas IR; Camacho LA; Teixeira-Carvalho A; Martins-Filho OA
    PLoS Negl Trop Dis; 2018 Jun; 12(6):e0006462. PubMed ID: 29879134
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A clinician's perspective on yellow fever vaccine-associated neurotropic disease.
    Lecomte E; Laureys G; Verbeke F; Domingo Carrasco C; Van Esbroeck M; Huits R
    J Travel Med; 2020 Nov; 27(7):. PubMed ID: 32965473
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Risk of yellow fever vaccine-associated viscerotropic disease among the elderly: a systematic review.
    Rafferty E; Duclos P; Yactayo S; Schuster M
    Vaccine; 2013 Dec; 31(49):5798-805. PubMed ID: 24079979
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical and immunological insights on severe, adverse neurotropic and viscerotropic disease following 17D yellow fever vaccination.
    Silva ML; Espírito-Santo LR; Martins MA; Silveira-Lemos D; Peruhype-Magalhães V; Caminha RC; de Andrade Maranhão-Filho P; Auxiliadora-Martins M; de Menezes Martins R; Galler R; da Silva Freire M; Marcovistz R; Homma A; Teuwen DE; Elói-Santos SM; Andrade MC; Teixeira-Carvalho A; Martins-Filho OA
    Clin Vaccine Immunol; 2010 Jan; 17(1):118-26. PubMed ID: 19906894
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Usefulness of a Duplex RT-qPCR during the Recent Yellow Fever Brazilian Epidemic: Surveillance of Vaccine Adverse Events, Epizootics and Vectors.
    Queiroz ALN; Barros RS; Silva SP; Rodrigues DSG; Cruz ACR; Dos Santos FB; Vasconcelos PFC; Tesh RB; Nunes BTD; Medeiros DBA
    Pathogens; 2021 Jun; 10(6):. PubMed ID: 34204910
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Previous biological therapy and impairment of the IFN-γ/IL-10 axis are associated with low immune response to 17DD-YF vaccination in patients with spondyloarthritis.
    Casagrande TZ; Costa-Rocha IAD; Gavi MBRO; Miyamoto ST; Martins PC; Serrano ÉV; Dinis VG; Machado KLLL; Gouvea SA; Caser LC; Campi-Azevedo AC; Teixeira-Carvalho A; Peruhype-Magalhães V; Bissoli MF; Gouvea MDPG; Lima SMB; Miranda EH; Trindade GF; Lyra DGP; Burian APN; Neto LFDSP; da Mota LMH; Martins-Filho OA; Valim V
    Vaccine; 2022 Jul; 40(32):4580-4593. PubMed ID: 35728990
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Surveillance system for adverse events following immunization against yellow fever in Burkina Faso in 2008. Good practice recommendations].
    Yaméogo TM; Breugelmans JG; Kambou JL; Badolo O; Tiendrebéogo S; Traoré E; Avokey F; Yactayo S
    Med Trop (Mars); 2009 Aug; 69(4):320-1. PubMed ID: 19725376
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reporting rates of yellow fever vaccine 17D or 17DD-associated serious adverse events in pharmacovigilance data bases: systematic review.
    Thomas RE; Lorenzetti DL; Spragins W; Jackson D; Williamson T
    Curr Drug Saf; 2011 Jul; 6(3):145-54. PubMed ID: 22122389
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adverse event reports following yellow fever vaccination, 2007-13.
    Lindsey NP; Rabe IB; Miller ER; Fischer M; Staples JE
    J Travel Med; 2016 May; 23(5):. PubMed ID: 27378369
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immune response during adverse events after 17D-derived yellow fever vaccination in Europe.
    Bae HG; Domingo C; Tenorio A; de Ory F; Muñoz J; Weber P; Teuwen DE; Niedrig M
    J Infect Dis; 2008 Jun; 197(11):1577-84. PubMed ID: 18419548
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Active and passive surveillance of yellow fever vaccine 17D or 17DD-associated serious adverse events: systematic review.
    Thomas RE; Lorenzetti DL; Spragins W; Jackson D; Williamson T
    Vaccine; 2011 Jun; 29(28):4544-55. PubMed ID: 21549787
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Yellow Fever Vaccine-Associated Viscerotropic Disease among Siblings, São Paulo State, Brazil.
    Fernandes EG; Gomes Porto VB; de Oliveira PMN; Duarte-Neto AN; de Sousa Maia ML; Lignani LK; Nogueira JS; Teixeira GV; Iglezias SD; Blanco RM; Sato HK
    Emerg Infect Dis; 2023 Mar; 29(3):493-500. PubMed ID: 36823036
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety profile of fractional dosing of the 17DD Yellow Fever Vaccine among males and females: Experience of a community-based pharmacovigilance in Kinshasa, DR Congo.
    Nzolo D; Engo Biongo A; Kuemmerle A; Lusakibanza M; Lula Y; Nsengi N; Nsibu Ndosimao C; Tona Lutete G; Van Geertruyden JP
    Vaccine; 2018 Oct; 36(41):6170-6182. PubMed ID: 30190119
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Review of the risks and benefits of yellow fever vaccination including some new analyses.
    Monath TP
    Expert Rev Vaccines; 2012 Apr; 11(4):427-48. PubMed ID: 22551029
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Yellow fever vaccine-associated neurotropic disease (YEL-AND) - A case report.
    Florczak-Wyspiańska J; Nawotczyńska E; Kozubski W
    Neurol Neurochir Pol; 2017; 51(1):101-105. PubMed ID: 27707454
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Influence of the IL-1Ra gene polymorphism on in vivo synthesis of IL-1Ra and IL-1beta after live yellow fever vaccination.
    Hacker UT; Erhardt S; Tschöp K; Jelinek T; Endres S
    Clin Exp Immunol; 2001 Sep; 125(3):465-9. PubMed ID: 11531955
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Booster dose after 10 years is recommended following 17DD-YF primary vaccination.
    Campi-Azevedo AC; Costa-Pereira C; Antonelli LR; Fonseca CT; Teixeira-Carvalho A; Villela-Rezende G; Santos RA; Batista MA; Campos FM; Pacheco-Porto L; Melo Júnior OA; Hossell DM; Coelho-dos-Reis JG; Peruhype-Magalhães V; Costa-Silva MF; de Oliveira JG; Farias RH; Noronha TG; Lemos JA; von Doellinger Vdos R; Simões M; de Souza MM; Malaquias LC; Persi HR; Pereira JM; Martins JA; Dornelas-Ribeiro M; Vinhas Ade A; Alves TR; Maia Mde L; Freire Mda S; Martins Rde M; Homma A; Romano AP; Domingues CM; Tauil PL; Vasconcelos PF; Rios M; Caldas IR; Camacho LA; Martins-Filho OA
    Hum Vaccin Immunother; 2016; 12(2):491-502. PubMed ID: 26360663
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adverse events associated with 17D-derived yellow fever vaccination--United States, 2001-2002.
    Centers for Disease Control and Prevention (CDC)
    MMWR Morb Mortal Wkly Rep; 2002 Nov; 51(44):989-93. PubMed ID: 12455906
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.